| CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment Y Jin, Z Desta, V Stearns, B Ward, H Ho, KH Lee, T Skaar, AM Storniolo, ... Journal of the National Cancer Institute 97 (1), 30-39, 2005 | 1175 | 2005 |
| Clinical significance of the cytochrome P450 2C19 genetic polymorphism Z Desta, X Zhao, JG Shin, DA Flockhart Clinical pharmacokinetics 41, 913-958, 2002 | 1171 | 2002 |
| Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine V Stearns, MD Johnson, JM Rae, A Morocho, A Novielli, P Bhargava, ... Journal of the National Cancer Institute 95 (23), 1758-1764, 2003 | 1034 | 2003 |
| Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes MP Goetz, JM Rae, VJ Suman, SL Safgren, MM Ames, DW Visscher, ... Journal of Clinical Oncology 23 (36), 9312-9318, 2005 | 982 | 2005 |
| Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6 Z Desta, BA Ward, NV Soukhova, DA Flockhart Journal of Pharmacology and Experimental Therapeutics 310 (3), 1062-1075, 2004 | 836 | 2004 |
| The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate … BA Ward, JC Gorski, DR Jones, SD Hall, DA Flockhart, Z Desta Journal of Pharmacology and Experimental Therapeutics 306 (1), 287-300, 2003 | 708 | 2003 |
| The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen MP Goetz, SK Knox, VJ Suman, JM Rae, SL Safgren, MM Ames, ... Breast cancer research and treatment 101, 113-121, 2007 | 690 | 2007 |
| Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: Implication for optimization of breast cancer treatment S Borges, Z Desta, L Li, TC Skaar, BA Ward, A Nguyen, Y Jin, ... Clinical Pharmacology & Therapeutics 80 (1), 61-74, 2006 | 572 | 2006 |
| Pharmacological Characterization of 4-hydroxy-N-desmethyl Tamoxifen, a Novel Active Metabolite of Tamoxifen MD Johnson, H Zuo, KH Lee, JP Trebley, JM Rae, RV Weatherman, ... Breast cancer research and treatment 85, 151-159, 2004 | 572 | 2004 |
| Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen YC Lim, Z Desta, DA Flockhart, TC Skaar Cancer chemotherapy and pharmacology 55, 471-478, 2005 | 364 | 2005 |
| Significant effect of polymorphisms in CYP2D6 and ABCC2 on clinical outcomes of adjuvant tamoxifen therapy for breast cancer patients K Kiyotani, T Mushiroda, CK Imamura, N Hosono, T Tsunoda, M Kubo, ... Journal of Clinical Oncology 28 (8), 1287, 2010 | 276 | 2010 |
| Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro Z Desta, T Saussele, B Ward, J Blievernicht, L Li, K Klein, DA Flockhart, ... Future Medicine Ltd 8 (6), 547-558, 2007 | 262 | 2007 |
| Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A Z Desta, NV Soukhova, DA Flockhart Antimicrobial agents and chemotherapy 45 (2), 382-392, 2001 | 236 | 2001 |
| Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study WJ Irvin Jr, CM Walko, KE Weck, JG Ibrahim, WK Chiu, EC Dees, ... Journal of clinical oncology 29 (24), 3232, 2011 | 220 | 2011 |
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing JJ Lima, CD Thomas, J Barbarino, Z Desta, SL Van Driest, N El Rouby, ... Clinical Pharmacology & Therapeutics 109 (6), 1417-1423, 2021 | 215 | 2021 |
| Cytochrome P450 pharmacogenetics as a predictor of toxicity and clinical response to pulse cyclophosphamide in lupus nephritis K Takada, M Arefayene, Z Desta, CH Yarboro, DT Boumpas, JE Balow, ... Arthritis & Rheumatism: Official Journal of the American College of …, 2004 | 202 | 2004 |
| Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells YC Lim, L Li, Z Desta, Q Zhao, JM Rae, DA Flockhart, TC Skaar Journal of Pharmacology and Experimental Therapeutics 318 (2), 503-512, 2006 | 184 | 2006 |
| Impact of proton pump inhibitors on the effectiveness of clopidogrel after coronary stent placement: the clopidogrel Medco outcomes study RP Kreutz, EJ Stanek, R Aubert, J Yao, JA Breall, Z Desta, TC Skaar, ... Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 30 (8 …, 2010 | 179 | 2010 |
| Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7 … ET Ogburn, DR Jones, AR Masters, C Xu, Y Guo, Z Desta Drug Metabolism and Disposition 38 (7), 1218-1229, 2010 | 168 | 2010 |
| Proton pump inhibitors effect on clopidogrel effectiveness: the Clopidogrel Medco Outcomes Study RE Aubert, RS Epstein, JR Teagarden, F Xia, J Yao, Z Desta, T Skaar, ... Circulation 118 (suppl_18), S_815-S_815, 2008 | 165 | 2008 |
